Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + fluorouracil + calcium folinate + irinotecan + capecitabine
- Development stage
- Unknown
- Lead developer
- TransThera Biosciences
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination refers to the chemotherapy control arm used in TransThera Sciences' Phase III clinical trial (NCT05950334) for patients with advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 alterations. The arm consists of investigator-selected standard-of-care regimens, which may include mFOLFOX (oxaliplatin, fluorouracil, and calcium folinate), XELIRI (irinotecan and capecitabine), or irinotecan monotherapy. These agents function through various cytotoxic mechanisms: oxaliplatin is a platinum-based agent that causes DNA cross-linking; fluorouracil and its oral prodrug capecitabine are antimetabolites that inhibit thymidylate synthase to disrupt DNA synthesis; and irinotecan is a topoisomerase I inhibitor that induces double-strand DNA breaks. Calcium folinate is typically administered alongside fluorouracil to enhance its binding to thymidylate synthase, thereby increasing its cytotoxic efficacy.
- Other names
- mFOLFOXXELIRI
02
Targets
DNATOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on oxaliplatin + fluorouracil + calcium folinate + irinotecan + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + fluorouracil + calcium folinate + irinotecan + capecitabine.